Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of California, San Francisco
The OMEGA-SPM-DOSE trial and the OMEGA-SPM-PAD trial are two parts of a pilot study which aims to investigate the effect of a novel formulation of a nutritional supplement containing highly concentrated n-3 PUFA metabolites (SPM Emulsion) on the metabolo-lipidomic profile of healthy volunteers and patients with Peripheral Arterial Disease(PAD). Ten healthy volunteers and ten patients with PAD will participate in Part 1a, the "OMEGA-SPM-DOSE Study". A follow-up, placebo controlled, prospective study on the best dosing modality determined in Phase 1a will then take place in a PAD and OA population (n=12), Phase 1b - the "OMEGA-SPM-PAD Study". Specific measurements will include targeted metabolo-lipidomic profiling, established markers of inflammation, and functional monocyte and macrophage assays. The proposed studies have the potential to provide important new insights on the role of nutritional interventions in PAD.
Age
Any age
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy Volunteers:
Age 20-80
PAD Patients:
Mild claudication to rest pain (Rutherford 1-4)
Resting or exercise ABI \< 0.9 or TBI \< 0.6
Age 40 and more
OA Patients:
Lower extremity (hip or knee) OA
You may not be if
PAD, OA Patients and Healthy Volunteers:
Plan to undergo surgical procedure or PVI for treatment of PAD within one month